Bicara Therapeutics Inc.

BCAX Nasdaq SEC CIK 2023658
Follow Bicara Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$71.2M −96.1% vs same quarter last year
EPS, diluted −$1.04 −55.2% vs same quarter last year
Operating cash flow −$56.1M −91.9% vs same quarter last year
Operating income −$75.7M −86.1% vs same quarter last year
Net income by quarter
−$21M
−$36.8M
−$27.4M
−$36.3M
−$37.4M
−$56.2M
−$55.4M
−$71.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$150M−$100M−$50M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$138M
FY24−$68M
FY23−$52M
FY22-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$107.1M
FY24−$74.8M
FY23−$46.2M
FY22-